Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical trial to explore ...

Boehringer Ingelheim to evaluate combination of DLL3-targeting T-cell engager plus PD-L1/VEGF-A bispecific antibody in small cell lung cancer: Ingelheim, Germany Saturday, April 1 ...

The financing combines a $50M Series D investment by Boehringer Ingelheim with additional dedicated funding to support commercialization. As part ...

“[Boehringer Ingelheim] had little incentive to investigate the dangers in a product that was producing over $1 billion in ...

Boehringer Ingelheim and Click Therapeutics are restructuring their marketing deal for the software-based schizophrenia ...

The investment is in Click Therapeutics, which co-developed an app-based treatment designed to help people with schizophrenia ...

"Achieving carbon neutrality in our owned manufacturing operations marks a significant milestone in Boehringer Ingelheim's decarbonization strategy," said Andy Brehm, Executive Director, U.S. Site ...

With weight loss candidates still in the clinic, the company has launched a health unit aimed at the flourishing therapeutic area.

In honor of Heartworm Awareness Month, Greater Good Charities, in cooperation with Boehringer Ingelheim, the maker of NexGard® PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets) which ...

Boehringer Ingelheim has amended its partnership with Click Therapeutics on a digital therapeutic (DTx) for schizophrenia, ...

Global R&D investments rose to EUR 6.4 billion, representing 22.9% of group net sales, across its markets ...

Ecuador aims to become one of the first rabies free countries in Latin America.• Joint efforts with the Ministry of Public Health focus on vaccination, education and epidemiological surveillance.